We are live on ! Find out more
PR

PSP Research Portfolio holdings

AUM $188M
This Fund
S&P 500
This Quarter Est. Return
+15.6%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$188M
AUM Growth
+$46.6M
Cap. Flow
+$25.8M
Cap. Flow %
13.71%
Top 10 Hldgs %
88.03%
Holding
89
New
10
Increased
1
Reduced
31
Closed
14

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$38.5M
2
LQDA icon
Liquidia Corp
LQDA
+$268K
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$213K
4
AVBP icon
ArriVent BioPharma
AVBP
+$208K
5
KRYS icon
Krystal Biotech
KRYS
+$207K

Top Sells

Rank Stock Value
1
SERA icon
Sera Prognostics
SERA
+$4.87M
2
DFTX
Definium Therapeutics
DFTX
+$613K
3
TYRA icon
Tyra Biosciences
TYRA
+$613K
4
CYTK icon
Cytokinetics
CYTK
+$547K
5
CMPS
Compass Pathways
CMPS
+$538K

Sector Composition

Rank Sector Weight
1 Healthcare 14.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
State Street SPDR S&P Biotech ETF
XBI
$11.8B
$90.2M 48.01%
570,000
+285,100
+100% +$38.5M
SGOV icon
2
iShares 0-3 Month Treasury Bond ETF
SGOV
$104B
$70.5M 37.51%
700,000
– –
RPRX icon
3
Royalty Pharma
RPRX
$27.6B
$617K 0.33%
11,000
– –
NRIX icon
4
Nurix Therapeutics
NRIX
$2.8B
$607K 0.32%
25,000
-3,700
-13% -$63K
INCY icon
5
Incyte
INCY
$26.3B
$601K 0.32%
5,300
– –
ARGX icon
6
argenx
ARGX
$63.8B
$595K 0.32%
641
– –
IRON icon
7
Disc Medicine
IRON
$3.16B
$585K 0.31%
8,000
– –
RAPP
8
Rapport Therapeutics
RAPP
$2.46B
$583K 0.31%
14,000
– –
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$2.61B
$568K 0.3%
17,000
-5,100
-23% -$127K
TRVI icon
10
Trevi Therapeutics
TRVI
$2.56B
$560K 0.3%
30,000
– –
GLUE icon
11
Monte Rosa Therapeutics
GLUE
$1.24B
$557K 0.3%
23,000
-5,000
-18% -$94.5K
TGTX icon
12
TG Therapeutics
TGTX
$8.48B
$549K 0.29%
10,000
-3,000
-23% -$123K
HALO icon
13
Halozyme
HALO
$12.4B
$548K 0.29%
7,000
-1,026
-13% -$70K
IONS icon
14
Ionis Pharmaceuticals
IONS
$10.6B
$539K 0.29%
6,800
– –
PHVS icon
15
Pharvaris
PHVS
$2.61B
$519K 0.28%
15,000
-5,000
-25% -$151K
ARQT icon
16
Arcutis Biotherapeutics
ARQT
$3.12B
$517K 0.27%
19,700
– –
AUPH icon
17
Aurinia Pharmaceuticals
AUPH
$2.23B
$509K 0.27%
30,000
– –
NBIX icon
18
Neurocrine Biosciences
NBIX
$15.6B
$506K 0.27%
3,000
-848
-22% -$126K
IMVT icon
19
Immunovant
IMVT
$8.99B
$501K 0.27%
13,000
-6,200
-32% -$189K
ACAD icon
20
Acadia Pharmaceuticals
ACAD
$5.27B
$500K 0.27%
19,766
– –
PTCT icon
21
PTC Therapeutics
PTCT
$6.13B
$489K 0.26%
6,000
– –
CLDX icon
22
Celldex Therapeutics
CLDX
$3.24B
$484K 0.26%
13,000
– –
IMCR icon
23
Immunocore
IMCR
$1.93B
$481K 0.26%
15,141
– –
DFTX
24
Definium Therapeutics
DFTX
$6.02B
$470K 0.25%
10,000
-24,800
-71% -$613K
COGT icon
25
Cogent Biosciences
COGT
$6.39B
$464K 0.25%
12,000
– –
1
2 3 4

Similar funds

IJWM
Inman Jager Wealth Management Hattiesburg, Mississippi $188M AUM 19.49% 1-Year Est. Return
TCPG
Trivant Custom Portfolio Group San Diego, California $188M AUM 23.55% 1-Year Est. Return
KCPT
Kingstone Capital Partners Texas Frisco, Texas $188M AUM 26.67% 1-Year Est. Return
DWS
Dynamic Wealth Strategies Granite Bay, California $188M AUM 18.55% 1-Year Est. Return
RMSCM
R.M. Sincerbeaux Capital Management New York $188M AUM 12.59% 1-Year Est. Return
AWP
Astra Wealth Partners Jersey City, New Jersey $188M AUM 26.79% 1-Year Est. Return
AIMA
Ables Iannone Moore & Associates Savannah, Georgia $188M AUM 26.75% 1-Year Est. Return
CFP
Comprehensive Financial Planning East Petersburg, Pennsylvania $188M AUM 48.26% 1-Year Est. Return

PSP Research's Q2 2026 Portfolio in Review

As of Q2 2026, PSP Research held 89 positions worth $188M, up 33% from $141M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

PSP Research deployed $25.8M of net new capital in Q2 2026, opening 10 new positions and adding to 1 existing holding. Its largest new stake was Liquidia Corp: 5,000 shares worth $399K.

By sector, the portfolio is most concentrated in Healthcare at 14% of assets, down from 24% a quarter earlier.

On the sell side, the largest reduction was Definium Therapeutics, an estimated $613K trimmed.

  • PSP Research's largest Q2 2026 buy was Liquidia Corp: 5,000 shares worth $399K.
  • PSP Research added most to State Street SPDR S&P Biotech ETF in Q2 2026, an estimated $38.5M increase.
  • PSP Research's biggest Q2 2026 reduction was Definium Therapeutics, cutting an estimated $613K.
  • PSP Research fully exited Sera Prognostics in Q2 2026, selling an estimated $4.87M.
  • PSP Research's ten largest holdings make up 88% of its $188M portfolio in Q2 2026.
  • PSP Research opened 10 new positions and closed 14 in Q2 2026.
  • PSP Research's portfolio value rose 33% quarter-over-quarter to $188M.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.